Jasper Therapeutics, Inc.
Jasper Therapeutics is a clinical-stage biotechnology company developing therapeutics for mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria and asthma. Its lead product candidate, briquilimab, is a monoclonal antibody designed to block signaling through the KIT receptor on mast and stem cells. Jasper is conducting clinical studies of briquilimab in CSU, CIndU and asthma, and is evaluating additional mast cell indications. The company has discontinued its programs in stem cell transplant conditioning and is exclusively focused on mast cell driven diseases. Jasper aims to develop and commercialize therapies for these conditions, with briquilimab intended for use on its own or, in some cases, with other therapeutics. It holds an exclusive license from Amgen for briquilimab’s development and commercialization in all indications and territories worldwide. Jasper Therapeutics is headquartered in Redwood City, California.
No SEC Form 4 filings for $JSPR in the last 30 days.
See all $JSPR insider activity →Jasper Therapeutics (JSPR) shares dropped 14% after announcing a 1-for-30 reverse stock split, reducing shares outstanding from 33.3M to 1.11M by November 6, 2026, according to a press release.
Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Jasper Therapeutics Announces 1-for-30 Reverse Stock Split REDWOOD CITY, Calif., November 4, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of
Jasper Therapeutics completed enrollment of 18 patients in the IgA nephropathy cohort of its Phase 2 vensobafusp alfa study, with interim data expected by year-end 2026. The company also plans to expand the study with an FSGS cohort in Q1 2027. Vensobafusp alfa is a dual-target complement inhibitor being evaluated for multiple renal diseases.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning JSPR (Jasper Therapeutics, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 2 bearish.
Recent JSPR coverage spans corporate actions and financial news.
The reverse split is likely to exert downward pressure as investors adjust to the reduced share count and perceived dilution of liquidity.
The reverse split will reduce share count and raise the per‑share price, potentially limiting liquidity and prompting short‑term price pressure.
Enrollment completion removes a near‑term execution risk and signals the study is on schedule, which may lift sentiment.
Enrollment completion signals progress toward interim data, which could drive the stock if results are positive.
Analyst upgrade may lift the stock as investors reassess valuation.
AlphAI scores every news story that mentions JSPR with an AI model for sentiment and relevance, and aggregates insider trades from Jasper Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Jasper Therapeutics (JSPR) shares dropped 14% after announcing a 1-for-30 reverse stock split, reducing shares outstanding from 33.3M to 1.11M by November 6, 2026, according to a press release.
1 min readJasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Jasper Therapeutics Announces 1-for-30 Reverse Stock Split REDWOOD CITY, Calif., November 4, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of
2 min readJasper Therapeutics completed enrollment of 18 patients in the IgA nephropathy cohort of its Phase 2 vensobafusp alfa study, with interim data expected by year-end 2026. The company also plans to expand the study with an FSGS cohort in Q1 2027. Vensobafusp alfa is a dual-target complement inhibitor being evaluated for multiple renal diseases.
1 min readJasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy Initial Stage 1 data evaluating vensobafusp alfa in IgAN expected by year-end 2026 Announces expansion cohort i
1 min readWilliam Blair resumed coverage on Jasper Therapeutics (NASDAQ:JSPR) with an outperform rating, citing the potential of KP-104 for treating complement-mediated diseases. The firm estimates peak sales of $1.6B and expects Phase III trials in 2027. JSPR stock trades at $0.50 with a $16.49M market cap, but analysts set a $20 price target. The company reported Q2 2026 earnings beating expectations and completed an all-stock acquisition of Kira Pharmaceuticals, altering ownership structure.
2 min readJasper Therapeutics (JSPR) has initiated an offer to purchase all outstanding warrants to buy its common stock at $0.324 per warrant. The move aims to reduce potential dilution and provide clarity on the company's capital structure. The offer, open until November 6, 2026, is not conditioned on a minimum number of warrants being tendered. If all warrants are tendered, the company expects to pay out approximately $4.0 million from cash on hand.
1 min readJasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 30, 2026, Jasper Therapeutics, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, a total of 21,747,865 shares of the Company’s voting common sto
1 min readJasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 23, 2026, Herb Cross submitted his resignation, effective as of October 9, 2026, as Chief Financial Officer,
2 min readJasper Therapeutics (JSPR) appointed Lisa Pitt and Shiguang Liu to key regulatory and clinical roles. The company reported a Q2 2026 net loss of $2.76M and has $7.3M in cash. It plans FDA meetings for KP-104 and Briquilimab in 2027. JSPR stock is up 5.24% in after-hours trading.
2 min readJasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 - Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 21, 2026, Jasper Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, base
2 min read
